Bei Zhang

3.5k total citations
191 papers, 2.4k citations indexed

About

Bei Zhang is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Surgery. According to data from OpenAlex, Bei Zhang has authored 191 papers receiving a total of 2.4k indexed citations (citations by other indexed papers that have themselves been cited), including 87 papers in Oncology, 57 papers in Pulmonary and Respiratory Medicine and 42 papers in Surgery. Recurrent topics in Bei Zhang's work include Colorectal Cancer Treatments and Studies (32 papers), Cancer Immunotherapy and Biomarkers (27 papers) and Gastric Cancer Management and Outcomes (18 papers). Bei Zhang is often cited by papers focused on Colorectal Cancer Treatments and Studies (32 papers), Cancer Immunotherapy and Biomarkers (27 papers) and Gastric Cancer Management and Outcomes (18 papers). Bei Zhang collaborates with scholars based in China, United States and Hong Kong. Bei Zhang's co-authors include Chang Jiang, Wenzhuo He, Huijuan Qiu, Liangping Xia, Guifang Guo, Chenxi Yin, Guifang Guo, Yuanyuan Huang, Xiuyu Cai and Yixin Zhou and has published in prestigious journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and The Journal of Immunology.

In The Last Decade

Bei Zhang

173 papers receiving 2.3k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Bei Zhang China 26 942 682 464 394 357 191 2.4k
Jian Dong China 26 586 0.6× 939 1.4× 306 0.7× 527 1.3× 454 1.3× 96 2.4k
Yasuhito Kobayashi Japan 24 700 0.7× 815 1.2× 392 0.8× 328 0.8× 341 1.0× 85 2.2k
Hee Seung Lee South Korea 27 934 1.0× 776 1.1× 501 1.1× 568 1.4× 577 1.6× 150 2.3k
Sandra Cerda United States 30 716 0.8× 649 1.0× 468 1.0× 236 0.6× 404 1.1× 72 2.2k
Shigemi Matsumoto Japan 26 1.6k 1.7× 866 1.3× 636 1.4× 380 1.0× 557 1.6× 136 3.2k
Ming Lu China 16 780 0.8× 514 0.8× 499 1.1× 247 0.6× 610 1.7× 60 2.4k
José Luís Zamora Manzano Spain 26 1.3k 1.3× 890 1.3× 557 1.2× 421 1.1× 254 0.7× 106 2.2k
Naoki Nagata Japan 28 1.0k 1.1× 1.2k 1.8× 439 0.9× 236 0.6× 507 1.4× 136 3.0k
Olorunseun O. Ogunwobi United States 29 686 0.7× 1.2k 1.7× 463 1.0× 1.1k 2.8× 465 1.3× 86 2.8k
Nikolaos Garmpis Greece 21 414 0.4× 749 1.1× 253 0.5× 296 0.8× 321 0.9× 127 1.7k

Countries citing papers authored by Bei Zhang

Since Specialization
Citations

This map shows the geographic impact of Bei Zhang's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Bei Zhang with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Bei Zhang more than expected).

Fields of papers citing papers by Bei Zhang

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Bei Zhang. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Bei Zhang. The network helps show where Bei Zhang may publish in the future.

Co-authorship network of co-authors of Bei Zhang

This figure shows the co-authorship network connecting the top 25 collaborators of Bei Zhang. A scholar is included among the top collaborators of Bei Zhang based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Bei Zhang. Bei Zhang is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Wang, Hongxia, Bei Zhang, Yingxin Zhao, et al.. (2025). Alectinib combined with VRCD and BV monoclonal antibody for the treatment of ALK-positive large B-cell lymphoma: a case report and literature review. Frontiers in Oncology. 14. 1480880–1480880.
2.
Zhou, Mengting, Cuiping Li, Wěi Li, et al.. (2025). INSL3 promotes macrophage polarization to an immunosuppressive phenotype via the cAMP downstream signaling pathway and Akt/mTOR pathway. International Immunopharmacology. 154. 114540–114540. 1 indexed citations
3.
Su, Xin, et al.. (2025). Burden and trends of drug use disorders in young adults: global insights from GBD 2021. Frontiers in Psychiatry. 16. 1503564–1503564.
4.
5.
Zhou, Qian, Weihao Luo, Bei Zhang, et al.. (2024). Design, synthesis, and evaluation of quinolin-2(1H)-ones as PDE1 inhibitors for the treatment of inflammatory bowel disease. Bioorganic Chemistry. 154. 107979–107979. 1 indexed citations
6.
Huang, Yan, et al.. (2024). Congenital Sternoclavicular Sinus—Case Series of a Rare Lower Neck Deformity. The Laryngoscope. 134(10). 4402–4408.
7.
Zhang, Bei, Zhimin Zou, Junjie Cai, et al.. (2024). Discovery and Optimization of Dihydroquinolin-2(1H)-ones as Novel Highly Selective and Orally Bioavailable Phosphodiesterase 5 Inhibitors for the Treatment of Pulmonary Arterial Hypertension. Journal of Medicinal Chemistry. 67(24). 22134–22144. 1 indexed citations
8.
Luo, Zhangyi, Yixian Huang, Shangyu Chen, et al.. (2024). Delivery of PARP inhibitors through 2HG-incorporated liposomes for synergistically targeting DNA repair in cancer. Cancer Letters. 604. 217268–217268. 4 indexed citations
9.
Rao, Wei, Ye Wang, Bei Zhang, et al.. (2024). Clinical value of [18F]AlF-NOTA-FAPI-04 PET/CT for assessing early-stage liver fibrosis in adult liver transplantation recipients compared with chronic HBV patients. Japanese Journal of Radiology. 42(5). 536–545. 7 indexed citations
10.
Wang, Xue, Feng Du, Jian Yue, et al.. (2023). Association between homologous recombination deficiency and outcomes with platinum and platinum-free chemotherapy in patients with triple-negative breast cancer. Cancer Biology and Medicine. 20(2). 155–168. 7 indexed citations
11.
Mao, Lipeng, et al.. (2023). Aging-related alternative splicing landscapes across human T cells. 9340007–9340007. 1 indexed citations
12.
Hu, Shiqi, Qian Zeng, Bei Zhang, et al.. (2023). Ugi reaction-assisted assembly of covalent PROTACs against glutathione peroxidase 4. Bioorganic Chemistry. 134. 106461–106461. 23 indexed citations
13.
14.
Sun, Xueguo, Bei Zhang, Qun Zhang, et al.. (2022). An analysis report on the application of immune checkpoint inhibitors after liver transplantation. Therapeutic Advances in Chronic Disease. 13. 374147910–374147910. 7 indexed citations
15.
Zhang, Bei, et al.. (2020). Integrated metabolomics and network pharmacology approach to reveal immunomodulatory mechanisms of Yupingfeng granules. Journal of Pharmaceutical and Biomedical Analysis. 194. 113660–113660. 12 indexed citations
16.
Liu, Shousheng, Yuanzhong Yang, Chang Jiang, et al.. (2018). Comparison of immunological characteristics between paired mismatch repair-proficient and -deficient colorectal cancer patients. Journal of Translational Medicine. 16(1). 195–195. 16 indexed citations
17.
Jiang, Chang, Yuhua Huang, Jiabin Lu, et al.. (2018). Perivascular cell coverage of intratumoral vasculature is a predictor for bevacizumab efficacy in metastatic colorectal cancer. Cancer Management and Research. Volume 10. 3589–3597. 8 indexed citations
18.
Zhang, Bei, et al.. (2017). Effects of Transcutaneous Electrical Acupoint Stimulation on Motor Functions and Self-Care Ability in Children with Cerebral Palsy. The Journal of Alternative and Complementary Medicine. 24(1). 55–61. 8 indexed citations
19.
Quan, Qi, Yuanyuan Huang, Huijuan Qiu, et al.. (2017). Impact of Serum Apolipoprotein A-I on Prognosis and Bevacizumab Efficacy in Patients with Metastatic Colorectal Cancer: a Propensity Score-Matched Analysis. Translational Oncology. 10(2). 288–294. 20 indexed citations
20.
He, Wenzhuo, Chang Jiang, Pengfei Kong, et al.. (2017). Primary Tumor Location as a Predictive Factor for First-line Bevacizumab Effectiveness in Metastatic Colorectal Cancer Patients. Journal of Cancer. 8(3). 388–394. 22 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Jian Dong Breakdown of academic impact, for papers by Yasuhito Kobayashi Breakdown of academic impact, for papers by Hee Seung Lee Breakdown of academic impact, for papers by Sandra Cerda Breakdown of academic impact, for papers by Shigemi Matsumoto Breakdown of academic impact, for papers by Ming Lu Breakdown of academic impact, for papers by José Luís Zamora Manzano Breakdown of academic impact, for papers by Naoki Nagata Breakdown of academic impact, for papers by Olorunseun O. Ogunwobi Breakdown of academic impact, for papers by Nikolaos Garmpis
Rankless by CCL
2026